spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  cluster headache 

 HSMN NewsFeed - 17 Jun 2021
Lilly Launches Think Talk Treat Migraine(TM) to Help Improve Diagnosis and Treatment of Migraine
Biopharmaceuticals Neurology
 HSMN NewsFeed - 6 Oct 2020
REYVOW(R) (lasmiditan) C-V Demonstrated Superior Pain Freedom At 2 Hours in At Least 2 of 3 Migraine Attacks in New Phase 3 Consistency of Effect Study
Biopharmaceuticals Neurology
 HSMN NewsFeed - 11 Sep 2020
REYVOW(TM) (lasmiditan) C-V Demonstrated Pain Freedom from Migraine Attacks At 60 Minutes and Up to 48 Hours in New Phase 3 Study
Biopharmaceuticals Neurology
 HSMN NewsFeed - 26 May 2020
Emgality(R) Shows Improvement in Work Productivity and Health and Well-Being Between Attacks in Patients with Migraine and a History of Preventive Treatment Failure
Biopharmaceuticals Neurology
 HSMN NewsFeed - 18 Dec 2019
Lilly Announces the Launch of TRIUMPH, the First, Long-Term, Real-World Evidence Study of Emgality(R) (galcanezumab-gnlm)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 2 Oct 2019
Upsher-Smith Laboratories Launches Tosymra(TM) (sumatriptan) Nasal Spray For The Acute Treatment Of Migraine In Adults
Biopharmaceuticals Neurology Drug Delivery Product Launch
 HSMN NewsFeed - 5 Aug 2019
Lilly Announces Positive Results for Emgality(R) (galcanezumab-gnlm) from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments
Biopharmaceuticals Neurology
 HSMN NewsFeed - 12 Jul 2019
AHS 2019: Post-Hoc Analyses of Phase 3 Pivotal Studies of Emgality(R) (galcanezumab-gnlm) Show Improvements in Daily Functioning and Reductions in Disability in Patients with Chronic and Episodic Migraine
Biopharmaceuticals Neurology
 HSMN NewsFeed - 11 Jul 2019
New England Journal of Medicine Publishes Positive Phase 3 Data for Emgality(R) (galcanezumab-gnlm) in Episodic Cluster Headache
Biopharmaceuticals Neurology
 HSMN NewsFeed - 14 Nov 2018
Lilly Submits New Drug Application to the FDA for Lasmiditan for Acute Treatment of Migraine, Receives Breakthrough Therapy Designation for Emgality(TM) (galcanezumab-gnlm) for Prevention of Episodic Cluster Headache
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 21 Sep 2018
Lilly Receives Positive CHMP Opinion for Emgality(TM) (galcanezumab) for the Prophylaxis of Migraine in Adults
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 29 Jun 2018
Amneal Announces Favorable Ruling Regarding Patent Validity for Zomig(R) (zolmitriptan) Nasal Spray
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 29 May 2018
TrioxBio Announces Fast Track Designation Granted by U.S. FDA to Raviten(R) for the Treatment of Intradialytic Hypotension
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 May 2018
Lilly's Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache
Biopharmaceuticals Neurology
 HSMN NewsFeed - 24 Apr 2018
AAN 2018: Lilly's Galcanezumab Significantly Reduced Monthly Migraine Headache Days in Patients with Migraine Who Previously Failed to Respond to Multiple Preventive Therapies
Biopharmaceuticals Neurology
 HSMN NewsFeed - 29 Jan 2018
gammaCore(R) Receives FDA Clearance for the Acute Treatment of Pain Associated with Migraine Headache in Adult Patients
Devices Neurology FDA
 HSMN NewsFeed - 11 Dec 2017
FDA Accepts Biologics License Application (BLA) to Review Galcanezumab for the Prevention of Migraine in Adults
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Nov 2017
electroCore Completes $70 Million Series B Funding Round
Devices Neurology Venture Capital
 HSMN NewsFeed - 11 Sep 2017
electroCore Announces Results from gammaCore(R) (non-invasive vagus nerve stimulator) Study in Migraine at the 18th Congress of the International Headache Society
Devices Neurology
 HSMN NewsFeed - 8 Sep 2017
IHC 2017: Lilly's Galcanezumab Demonstrates Positive Long-Term Safety Results for up to 12 Months in Patients with Migraine
Biopharmaceutical Neurology
 HSMN NewsFeed - 4 Aug 2017
Lilly Announces Positive Results for Second Phase 3 Study of Lasmiditan for the Acute Treatment of Migraine
Biopharmaceuticals Neurology
 HSMN NewsFeed - 12 May 2017
Lilly Announces Positive Results for Three Phase 3 Studies of Galcanezumab for the Prevention of Episodic and Chronic Migraine
Biopharmaceuticals Neurology
 HSMN NewsFeed - 18 Apr 2017
FDA Releases gammaCore(R), the First Non-Invasive Vagus Nerve Stimulation Therapy Applied at the Neck for Acute Treatment of Pain Associated with Episodic Cluster Headache in Adult Patients
Devices FDA
 HSMN NewsFeed - 18 Jan 2017
Lilly and CoLucid Pharmaceuticals Announce Agreement for Lilly To Acquire CoLucid
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 31 Oct 2016
Antares Pharma Appoints Fred M. Powell, Senior Vice President and Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 May 2016
Two-Year Study Results Show the Pulsante(R) Microstimulator Provides Sustained, Long-Term Relief for Cluster Headache Patients
Devices Neurology
 HSMN NewsFeed - 13 Apr 2016
Autonomic Technologies Appoints Niamh Pellegrini as President and Chief Executive Officer
Devices Neurology Personnel
 HSMN NewsFeed - 12 Apr 2016
Autonomic Technologies Appoints Niamh Pellegrini as President and Chief Executive Officer
Devices Neurology Personnel
 HSMN NewsFeed - 1 Apr 2016
NICE Provides Positive Guidance on electroCore's gammaCore Treatment for the Prevention and Acute Treatment of Migraine and Cluster Headache
Devices Neurology Regulatory
 HSMN NewsFeed - 14 Dec 2015
Antares Pharma Announces FDA Approval of Sumatriptan Injection USP
Biopharmaceuticals FDA
 HSMN NewsFeed - 25 Jun 2015
Autonomic Technologies Completes Transatlantic Series D Financing of $43.2M
Devices Neurology Venture Capital
 HSMN NewsFeed - 18 Jun 2015
Autonomic Technologies(R) Announces 200 Cluster Headache Patients Implanted With the Pulsante(TM) Microstimulator
Devices Neurology
 HSMN NewsFeed - 12 May 2015
Autonomic Technologies Raises USD 38M in a Transatlantic Series D Financing
Devices Neurology Venture Capital Personnel
 HSMN NewsFeed - 24 Apr 2014
Endo Acquires Rights to Sumavel(R) DosePro(R)
Biopharmaceuticals Drug Delivery Acquisitions
 HSMN NewsFeed - 9 Jan 2014
Mallinckrodt Pharmaceuticals and Zogenix to End Co-Promotion Agreement
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 17 Dec 2013
Zogenix Appoints Chief Medical Officer and Expands Medical Leadership Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Feb 2013
ATI Neurostimulation System(TM) Shown to be Highly Effective in Treating Cluster Headache – Results of a Multi-Centre European Study
Devices Neurology
 HSMN NewsFeed - 26 Nov 2012
Zogenix Appoints New Chief Commercial Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 8 Nov 2012
Zogenix Announces FDA Advisory Committee Review of Zohydro(TM) ER for the Management of Chronic Pain
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Jan 2011
SUMAVEL DosePro Receives Marketing Approval in Germany and the United Kingdom
Biopharmaceuticals Drug Delivery Regulatory
 HSMN NewsFeed - 6 Jan 2011
Zogenix and Desitin Announce Marketing Approval for SUMAVEL(R) DosePro(TM) in Germany and the United Kingdom
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 2 Aug 2010
Sagent Pharmaceuticals Announces Two New FDA Approvals: Sumatriptan Succinate Injection and Rocuronium Bromide Injection
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Jul 2010
Zogenix Secures $35 Million Debt Facility and Raises $15 Million Investment Capital
Biopharmaceuticals Drug Delivery Venture Capital
 HSMN NewsFeed - 22 Oct 2009
Zogenix and Astellas Announce Data Published Showing the Benefits of SUMAVEL(TM) DosePro(TM) Needle-Free Delivery System
Biopharmaceuticals Devices Drug Delivery
 HSMN NewsFeed - 14 Aug 2009
Winston Pharmaceuticals, Inc. Announces Re-Election of Joel E. Bernstein M.D. as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Aug 2009
Zogenix and Astellas Enter Exclusive Co-Promotion Agreement in the US for Newly Approved Sumavel(TM) DosePro(TM)
Biopharmaceuticals
 HSMN NewsFeed - 28 Jul 2009
Winston Pharmaceuticals, Inc. Announces Election of New Chief Executive Officer and Chairman of the Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Jul 2009
Sumavel(TM) DosePro(TM) (sumatriptan injection) Approved by FDA for Acute Migraine and Cluster Headache: First Product Featuring Novel DosePro Needle-Free Delivery System
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 May 2008
Par Pharmaceutical Acquires Spectrum Pharmaceutical's Interest In Sumatriptan Injection
Biopharmaceuticals
 HSMN NewsFeed - 7 May 2008
Spectrum Pharmaceuticals Receives $20 Million Cash Payment from Par Pharmaceutical for Sumatriptan Injection
Biopharmaceuticals
 HSMN NewsFeed - 17 Apr 2008
Zogenix Completes Management Team with Cynthia Robinson, Ph.D., CDO, & Mark Thompson, VP, Sales & Managed Markets
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 7 Apr 2008
Endo Pharmaceuticals Provides Updates on FROVA(R) and CHRONOGESIC(R) Clinical Development Programs
Biopharmaceuticals
 HSMN NewsFeed - 15 Nov 2007
Getting Ready Corporation and Winston Laboratories, Inc. Announce Merger Agreement
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 16 Mar 2007
Endo and Vernalis plc Announce Three-Month Extension of PDUFA Date for Frova(R) sNDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Nov 2006
Par Pharmaceutical Announces Agreement With GlaxoSmithKline to Settle Imitrex(R) Injection Patent Litigation
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 13 Nov 2006
Spectrum Pharmaceuticals Announces Agreement With GlaxoSmithKline to Settle Imitrex(R) Injection Patent Litigation
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 19 Jul 2006
Endo Pharmaceuticals and Vernalis plc Announce the Filing of the Supplemental NDA for Frova(R) for Short-Term Prevention of Menstrual Migraine
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 May 2006
Frova(R) Meets Primary Endpoint in Second Phase III Study for Prevention of Menstrual Migraine
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 8

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 8 additional stories matching:
cluster headache
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.